New Publication in NPJ Breast Cancer
Published:
We are pleased to announce the publication of a new collaborative research article, Estrogen prevents anti-tumor effects of Zoledronic acid in breast cancer through the NK and CD8+ T cell PD-1/PD-L1 axes, in npj Breast Cancer. Led by Prof. Penny Ottewell, the study investigates why the anti-cancer effects of zoledronic acid differ between pre- and postmenopausal women with breast cancer, and identifies immune mechanisms that may help explain this clinically important difference.
Zoledronic acid is widely used to reduce complications associated with bone metastasis and can also reduce breast cancer recurrence in postmenopausal women. However, clinical trials have shown that these anti-tumour benefits are strongly influenced by menopausal status. The study investigated how oestrogen influences the response to zoledronic acid, focusing on its effects on anti-tumour immunity in both bone and soft-tissue metastases.
Using preclinical models alongside patient samples from the AZURE clinical trial, the researchers found that zoledronic acid stimulates anti-tumour immune responses when oestrogen concentrations are low. These effects involve increased activity and tumour infiltration of immune populations including NK and CD8+ T cells. In contrast, high concentrations of oestrogen suppress these responses, reducing anti-tumour immune-cell activity and increasing expression of the immune checkpoints PD-1 on T and NK cells and PD-L1 on tumour cells.
Analysis of tumour samples from 1,729 patients enrolled in the AZURE trial provided further clinical support for these findings. PD-L1 expression was associated with menopausal status and response to zoledronic acid, with patients whose tumours were PD-L1-negative showing improved disease-free and overall survival and reduced recurrence following the addition of zoledronic acid to standard-of-care treatment.
Importantly, the experimental findings suggest that this oestrogen-driven immune suppression may be therapeutically actionable. Blocking the PD-1/PD-L1 immune-checkpoint axis restored the anti-tumour effects of zoledronic acid under high-oestrogen conditions, suggesting that combining zoledronic acid with immune-checkpoint inhibition could provide a strategy for extending its anti-metastatic benefits to a broader group of patients.
This work forms part of our ongoing collaboration with Prof. Ottewell and the Sheffield Laboratory for Dormancy and Metastasis, investigating the mechanisms that regulate breast cancer metastasis and identifying potential strategies to prevent metastatic disease.
